LivaNova PLC (LIVN) Formed Bullish Multiple Top; Buyers Could Thrive

May 23, 2018 - By Adrian Erickson

LivaNova PLC (NASDAQ:LIVN) Logo

The stock of LivaNova PLC (LIVN) shows a multiple tops pattern with $85.72 target or 3.00 % above today’s $83.22 share price. The 5 months chart pattern indicates low risk for the $4.03 billion company. It was reported on May, 23 by Finviz.com. If the $85.72 price target is reached, the company will be worth $120.93 million more.
Multiple tops are chart patterns with decent performance in a bull market. The failure rate is higher but the average decline is reasonable. Back-tests of such patterns show that the break even failure rate is 10%, the average rise: 19%, the throwback rate: 61% and the percentage of stocks meeting their price targets: 40%.

The stock decreased 0.93% or $0.78 during the last trading session, reaching $83.22. About 236,293 shares traded. LivaNova PLC (NASDAQ:LIVN) has risen 66.28% since May 23, 2017 and is uptrending. It has outperformed by 54.73% the S&P500.

Analysts await LivaNova PLC (NASDAQ:LIVN) to report earnings on August, 8. They expect $0.84 earnings per share, down 16.83 % or $0.17 from last year’s $1.01 per share. LIVN’s profit will be $40.69 million for 24.77 P/E if the $0.84 EPS becomes a reality. After $0.36 actual earnings per share reported by LivaNova PLC for the previous quarter, Wall Street now forecasts 133.33 % EPS growth.

Another recent and important LivaNova PLC (NASDAQ:LIVN) news was published by Seekingalpha.com which published an article titled: “LivaNova PLC 2018 Q1 – Results – Earnings Call Slides” on May 02, 2018.

LivaNova PLC, a medical device company, designs, develops, makes, and sells therapeutic solutions worldwide. The company has market cap of $4.03 billion. It operates in three businesses: Neuromodulation, Cardiac Surgery, and Cardiac Rhythm Management. It currently has negative earnings. The Neuromodulation business designs, develops, and markets its Vagus Nerve Stimulation Therapy System, an implantable device to treat drug-resistant epilepsy and treatment-resistant depression (TRD).

LivaNova PLC (NASDAQ:LIVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: